Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 12, 2012, Pages 1251-1260

  Dusetzina, Stacie B ^a   Busch, Alisa B ^a,b   Conti, Rena M ^c,d   Donohue, Julie M ^e   Caleb Alexander, G ^d,f,g   Huskamp, Haiden A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug utilization; FDA advisory; Metabolic risk; Pharmacoepidemiology; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84870722705     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3272     Document Type: Article

References (45)

1. Amiel JM, Mangurian CV, Ganguli R, et al. Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry 2008;21:613-618.
2. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473.
3. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
4. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010; 164:344-351.
5. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008;69:316-322.
6. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166:345-353.
7. Morrato EH, Cuffel B, Newcomer JW, et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009;29:26-32.
8. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24.
9. Morrato EH, Druss BG, Hartung DM, et al. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiol Drug Saf 2011;20:66-75.
10. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037-1042.
11. Valluri S, Zito JM, Safer DJ, et al. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care 2010;48:947-954.
12. Kaplan A. Consensus Panel Urges Monitoring for Metabolic Effects of Atypical Antipsychotics Psychiatric Times: UBM Medica; 2004.
13. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-1026.
14. Goode E. 3 Schizophrenia Drugs May Raise Diabetes Risk, Study Says The New York Times. The New York Times: New York; 2003.
15. Anand G. NEW ANTIPSYCHOTICS POSE A QUANDARY FOR FDA, DOCTORS. Wall St J 2003:1.
16. U.S. Food and Drug Administration. MedWatch Safety Information: Geodon (ziprasidone). 2004. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154977.htm Accessed 05/16/2011, 2011.
17. U.S. Food and Drug Administration. MedWatch Safety Information: Atypical Antipsychotic Drugs. 2005. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150688.htm Accessed 05/16/2011.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
19. Florida Agency for Health Care Administration. Agency for Health Care Administration Announces NEW Medicaid Preferred Drug List. 2005. Available at: http://www.fdhc.state.fl.us/executive/communications/press_releases/archive/2005/07_06_2005.shtml Accessed 05/16/2011.
20. Busch AB, Lehman AF, Goldman H, et al. Changes over time and disparities in schizophrenia treatment quality. Med Care 2009;47:199-207.
21. Busch AB, Frank RG, Lehman AF, et al. Schizophrenia, co-occurring substance use disorders and quality of care: the differential effect of a managed behavioral health care carve-out. Adm Policy Ment Health 2006;33:388-397.
22. Busch AB, Frank RG, Lehman AF. The effect of a managed behavioral health carve-out on quality of care for Medicaid patients diagnosed as having schizophrenia. Arch Gen Psychiatry 2004;61:442-448.
23. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care 2010;48:372-379.
24. Busch AB, Huskamp HA, Neelon B, et al. Longitudinal racial/ethnic disparities in antimanic medication use in bipolar-I disorder. Med Care 2009;47:1217-1228.
25. Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med 2010;153:633-640.
26. Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents. Arch Pediatr Adolesc Med 2009;163:357-364.
27. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994;151:1-36.
28. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50.
29. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886.
30. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000;Spec No:1-104.
31. Standards of medical care in diabetes--2011. Diabetes Care 2011;34 (Suppl 1):S11-61.
32. Busch AB, Frank RG, Sachs G, et al. Bipolar-I patient characteristics associated with differences in antimanic medication prescribing. Psychopharmacol Bull 2009; 42:35-49.
33. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-1060.
34. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Statistical methods in medical research 2011.
35. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199-200.
36. Philip NS, Mello K, Carpenter LL, et al. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 2008;20:15-20.
37. Constantine R, Tandon R. Changing trends in pediatric antipsychotic use in Florida's Medicaid program. Psychiatr Serv 2008;59:1162-1168.
38. Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008;59:523-525.
39. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 2007;33:654-656.
40. Druss BG, von Esenwein SA, Compton MT, et al. A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry 2010;167:151-159.
41. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24:S1-6.
42. Lester H, Tritter JQ, Sorohan H. Patients' and health professionals' views on primary care for people with serious mental illness: focus group study. BMJ 2005;330:1122.
43. Essock SM, Covell NH, Leckman-Westin E, et al. Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in new york state. Psychiatr Serv 2009;60:1595-1602.
44. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103:104-109.
45. Signorovitch J, Birnbaum H, Ben-Hamadi R, et al. Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change. J Clin Psychiatry 2011;72(6):787-94.